.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Managing ACS in elderly patients requires a nuanced understanding of physiological age. A recent study explores how gender and frailty interact to determine prognosis. While STEMI remains a high-risk presentation, biological reserves often dictate survival better than traditional risk factors. Therefore, clinical assessment is critical for these vulnerable individuals.
Notably, the study revealed a gender paradox. Although women were more likely to present with frailty, the female sex was a protective factor for mortality. Specifically, women showed a 42% lower risk of death compared to men over a one-year period. Consequently, gender-specific risk models may be necessary to improve accuracy in geriatric cardiology.
In addition, the Rockwood Clinical Frailty Scale (CFS) proved to be a robust predictor of mortality. Researchers found that frail patients faced more than triple the risk of death within a year. For instance, high CFS scores correlated strongly with poor long-term survival. Thus, clinicians should prioritize early frailty screening within 48 hours of admission to guide therapy.
Furthermore, the data strongly supports the use of invasive strategies. Percutaneous coronary intervention (PCI) was associated with a 56% reduction in mortality risk. However, many elderly patients still receive only conservative medical care. Moreover, the study confirms that invasive strategies yield better long-term outcomes than medical therapy alone, regardless of chronological age.
Finally, the study emphasized that STEMI presentations carry higher in-hospital mortality than NSTE-ACS. Early identification is vital. By combining frailty scores with diagnostic tools, doctors can improve patient counseling and risk stratification. As a result, patients receive more personalized and effective care plans.
Frailty serves as a significant independent predictor of mortality. Patients with higher frailty scores on the Rockwood scale have over three times the risk of death within one year compared to non-frail patients.
Yes, the study indicates that percutaneous coronary intervention (PCI) is highly beneficial. Invasive strategies were associated with a 56% reduction in the risk of mortality for patients aged 75 and older.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Study of 627 elderly ACS patients shows female sex and invasive PCI strategy protect against 1-year mortality, while frailty triples the risk of death....
5 months ago
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today
In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
